Effects of VitabridC on Skin Inflammation

Overview

Journal Ann Dermatol

Specialty Dermatology

Date 2017 Oct 3

PMID 28966510

Citations 2

Authors

Ji Hyun Lee

Yoon-Jae Jeon

Jung Hye Choi

Hae Young Kim

Tae-Yoon Kim

Affiliations

Soon will be listed here.

Abstract

Background: VitabridC is newly developed and composed of vitamin C and Vitabrid (lamellar, hydrated zinc oxide).

Objective: In this study, we aimed to investigate the effects of VitabridC on psoriasis and atopic dermatitis.

Methods: Mice with imiquimod-induced psoriasis or -induced atopic dermatitis were applied with VitabridC. The effects of VitabridC were evaluated by clinical features, histology, and immunologic features by examining cytokines and chemokines.

Results: In psoriasis model, VitabridC decreased epidermal thickness and reduced inflammatory cell infiltration. In atopic dermatitis model, VitabridC decreased dermal infiltration of inflammatory cells, epidermal hyperplasia, and hyperkeratosis. VitabridC reduced the expression levels of proinflammatory mediators such as interleukin (IL)-1β, IL-6, IL-8, IL-17A, IL-22, tumor necrosis factor-α, CXCL1, CCL17, and CCL20 as well as COX-2 in imiquimod-induced psoriatic skin lesions. Likewise, VitabridC reduced the expression levels of IL-4, IL-5, IL-13, thymic stromal lymphopoietin, and CCL4 in -induced skin lesions, and decreased the serum immunoglobulin E level in the atopic dermatitis mouse model. Particularly, the VitabridC-treated mice showed downregulated expressions of mitogen-activated protein kinase (MAPK), including extracellular signal-regulated kinase (ERK), p38, and MAPK/ERK kinase, as well as inhibited phosphorylation of nuclear factor-κB p65.

Conclusion: Taken together, these findings indicate that VitabridC exhibits anti-inflammatory activities and is a promising candidate as a treatment option for psoriasis or atopic dermatitis.

Citing Articles

Coencapsulation of Immunosuppressive Drug with Anti-Inflammatory Molecule in Pickering Emulsions as an Innovative Therapeutic Approach for Inflammatory Dermatoses.

Sintes M, Kovjenic P, Haine Hablal L, Serror K, Beladjine M, Parietti Montcuquet V JID Innov. 2024; 4(4):100273.

PMID: 39045393 PMC: 11264173. DOI: 10.1016/j.xjidi.2024.100273.

NXP081, DNA Aptamer-Vitamin C Complex Ameliorates DNFB-Induced Atopic Dermatitis in Balb/c Mice.

Lee S, Ahn H, Park Y, Kim J, Kim Y, Cho J Nutrients. 2023; 15(19).

PMID: 37836456 PMC: 10574402. DOI: 10.3390/nu15194172.

References

Johansen C, Kragballe K, Westergaard M, Henningsen J, Kristiansen K, Iversen L . The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol. 2005; 152(1):37-42. DOI: 10.1111/j.1365-2133.2004.06304.x. View

Gupta S, Sundaram C, Reuter S, Aggarwal B . Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta. 2010; 1799(10-12):775-87. PMC: 2955987. DOI: 10.1016/j.bbagrm.2010.05.004. View

Leung D . Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol. 1997; 107 Suppl 1:25-30. View

Bystry R, Aluvihare V, Welch K, Kallikourdis M, Betz A . B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol. 2001; 2(12):1126-32. DOI: 10.1038/ni735. View

Leung D, Soter N . Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol. 2001; 44(1 Suppl):S1-S12. DOI: 10.1067/mjd.2001.109815. View

Kaur I, Kapila M, Agrawal R . Role of novel delivery systems in developing topical antioxidants as therapeutics to combat photoageing. Ageing Res Rev. 2007; 6(4):271-88. DOI: 10.1016/j.arr.2007.08.006. View

Koo J . Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996; 14(3):485-96. DOI: 10.1016/s0733-8635(05)70376-4. View

Vane J, Bakhle Y, Botting R . Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998; 38:97-120. DOI: 10.1146/annurev.pharmtox.38.1.97. View

Nair R, Callis Duffin K, Helms C, Ding J, Stuart P, Goldgar D . Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009; 41(2):199-204. PMC: 2745122. DOI: 10.1038/ng.311. View

10.

Grossman R, Krueger J, Yourish D, Granelli-Piperno A, Murphy D, May L . Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989; 86(16):6367-71. PMC: 297840. DOI: 10.1073/pnas.86.16.6367. View

11.

Roh N, Han S, Youn H, Kim Y, Lee Y, Choe Y . Tissue and Serum Inflammatory Cytokine Levels in Korean Psoriasis Patients: A Comparison between Plaque and Guttate Psoriasis. Ann Dermatol. 2016; 27(6):738-43. PMC: 4695427. DOI: 10.5021/ad.2015.27.6.738. View

12.

Lansdown A, Mirastschijski U, Stubbs N, Scanlon E, Agren M . Zinc in wound healing: theoretical, experimental, and clinical aspects. Wound Repair Regen. 2007; 15(1):2-16. DOI: 10.1111/j.1524-475X.2006.00179.x. View

13.

Teunissen M, Koomen C, de Waal Malefyt R, Wierenga E, Bos J . Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998; 111(4):645-9. DOI: 10.1046/j.1523-1747.1998.00347.x. View

14.

Yalcin B, Guler Tezel G, Arda N, Erman M, Alli N . Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis. Anal Quant Cytol Histol. 2008; 29(6):358-64. View

15.

Xhauflaire-Uhoda E, Henry F, Pierard-Franchimont C, Pierard G . Electrometric assessment of the effect of a zinc oxide paste in diaper dermatitis. Int J Cosmet Sci. 2009; 31(5):369-74. DOI: 10.1111/j.1468-2494.2009.00505.x. View

16.

Haase I, Hobbs R, Romero M, Broad S, Watt F . A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis. J Clin Invest. 2001; 108(4):527-36. PMC: 209397. DOI: 10.1172/JCI12153. View

17.

Sampson H, Albergo R . Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis. J Allergy Clin Immunol. 1984; 74(1):26-33. DOI: 10.1016/0091-6749(84)90083-6. View

18.

Ziegler S, Artis D . Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol. 2010; 11(4):289-93. PMC: 2924817. DOI: 10.1038/ni.1852. View

19.

Pastore S, Mascia F, Mariotti F, Dattilo C, Mariani V, Girolomoni G . ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol. 2005; 174(8):5047-56. DOI: 10.4049/jimmunol.174.8.5047. View

20.

Mabuchi T, Takekoshi T, Hwang S . Epidermal CCR6+ γδ T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J Immunol. 2011; 187(10):5026-31. DOI: 10.4049/jimmunol.1101817. View